CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.67M | 10.18M | 1.46M | 864.00K | 889.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.67M | 10.18M | 1.46M | 864.00K | 889.00K |
| Cost of Revenue | 113.17M | 107.42M | 114.52M | 137.23M | 116.02M |
| Gross Profit | -100.50M | -97.24M | -113.07M | -136.37M | -115.13M |
| SG&A Expenses | 17.87M | 17.55M | 17.18M | 18.40M | 16.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 131.04M | 124.98M | 131.71M | 155.63M | 132.95M |
| Operating Income | -118.37M | -114.80M | -130.25M | -154.76M | -132.06M |
| Income Before Tax | -111.36M | -90.19M | -122.09M | -130.00M | -105.82M |
| Income Tax Expenses | 74.00K | 960.00K | 839.00K | 614.00K | 619.00K |
| Earnings from Continuing Operations | -111.44M | -91.15M | -122.93M | -130.61M | -106.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.44M | -91.15M | -122.93M | -130.61M | -106.44M |
| EBIT | -118.37M | -114.80M | -130.25M | -154.76M | -132.06M |
| EBITDA | -114.13M | -110.52M | -125.93M | -149.10M | -127.63M |
| EPS Basic | -1.15 | -0.94 | -1.28 | -1.37 | -1.17 |
| Normalized Basic EPS | -0.64 | -0.57 | -0.79 | -0.85 | -0.72 |
| EPS Diluted | -1.15 | -0.94 | -1.28 | -1.37 | -1.17 |
| Normalized Diluted EPS | -0.64 | -0.57 | -0.79 | -0.85 | -0.72 |
| Average Basic Shares Outstanding | 96.74M | 96.51M | 96.05M | 95.27M | 91.31M |
| Average Diluted Shares Outstanding | 96.74M | 96.51M | 96.05M | 95.27M | 91.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |